Related Experiment Video
Updated: Mar 29, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Recent advances in bladder urothelial carcinogenesis].
Géraldine Pignot1, Constance le Goux2, Ivan Bieche2
1Institut Paoli-Calmettes, service de chirurgie urologique, 13009 Marseille, France.
Bladder cancer prognosis is poor, but molecular insights reveal subtypes based on genetic alterations like FGFR3 and TP53. This enables personalized medicine and targeted therapies for better treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Bladder cancer is a significant cause of cancer mortality in France.
- Prognosis for muscle-invasive bladder tumors is poor due to limited effective treatments.
- Recent molecular biology and genome-wide studies have advanced understanding of bladder carcinogenesis.
Purpose:
- To review genetic and epigenetic alterations in bladder cancer.
- To explore the role of these alterations as theranostic markers.
- To discuss new targeted therapies within personalized medicine.
Summary:
- Key molecular alterations in bladder cancer include FGFR3, TP53, and HER2.
- These alterations allow for the classification of tumors into three distinct molecular subgroups.
- The review covers genetic and epigenetic changes, theranostic potential, and personalized therapeutic strategies.
Impact:
- Advances in understanding bladder cancer molecular profiles.
- Potential for improved theranostic markers in clinical oncology.
- Development of new targeted therapies for personalized bladder cancer treatment.
Related Concept Videos
Urinary Tract Infection II: Pathophysiology
Anatomy of the Genitourinary System II: Bladder and Urethra
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

